BioLargo报告称，尽管宠物产品诉讼导致收入下降，但现金收入达450万美元，无债务，并在关键技术领域取得了进展。 BioLargo reports $4.5M cash, no debt, and progress in key tech areas despite revenue drop from pet product lawsuit.

BioLargo公司报告说,截至2025年9月30日,现金结存为450万美元,没有债务,在伤口护理、外科产品、PFAS治疗及其CellinityTM电池平台接近商业化方面取得进展。 BioLargo, Inc. reported a $4.5 million cash balance and no debt as of September 30, 2025, with progress in wound care, surgical products, PFAS treatment, and its Cellinity™ battery platform nearing commercialization. 由于在被许可人不付款和未经授权的行动之后吊销了宠物气味产品许可证,促使联邦就知识产权对Poph Inc.提出诉讼,因此年复一年的收入下降。 Year-over-year revenue declined due to the revocation of a pet odor product license following a licensee’s non-payment and unauthorized actions, prompting a federal lawsuit against Pooph Inc. over intellectual property. 该公司指出,法律问题不会影响其他倡议,仍注重伙伴关系和扩大其清洁技术和医疗技术,但未来结果可能因市场条件和发展风险而异。 The company stated the legal issue won’t impact other initiatives and remains focused on partnerships and scaling its cleantech and healthcare technologies, though future results may vary due to market conditions and development risks.